PHGDH and cancer: Most of the in vitro studies on NCT-503 inhibition effects published over last decade show a similar pattern in terms of study design, regardless of the cancer type: (i) study of SSP augmentation and (ii) use of in vitro models for NCT-503 treatment investigation as an inhibitor of the SSP rate-limiting PHGDH.